Ritter Pharmaceuticals develops novel therapeutic products for gastrointestinal disease. The company focuses on products that modulate the human gut microbiome.
Dr. Sandborn is the chief of the gastroenterology division and director at the University of California San Diego Inflammatory Bowel Disease Center.
“We are excited to have Dr. Sandborn join Ritter Pharmaceuticals as a member of our medical advisory board. His years of experience in gastroenterology, vast industry knowledge and close relationships with the FDA will be a valuable resource as we advance our development of therapeutics to treat gastrointestinal diseases, and in particular our lead product candidate RP-G28 for patients with lactose intolerance,” said Ritter Pharmaceuticals CEO Michael Step.
More articles on gastroenterology:
3 GI physicians in the news – Oct. 16, 2015
ACG elects Dr. Kenneth DeVault president: 5 things to know
5 most-read GI/endoscopy stories – Week of Oct 12 to Oct. 16
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.